cilazapril, anhydrous has been researched along with Focal Segmental Glomerulosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, HS; Han, SW; Kim, HJ; Kim, SW; Lee, JU; Paik, DJ; Paik, SS; Park, IK; Park, MH; Ryu, JH | 1 |
| Futrakul, N; Futrakul, P; Kingwatanakul, P; Sensirivatana, R; Sitprija, V; Watana, D | 1 |
2 other study(ies) available for cilazapril, anhydrous and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cilazapril; Doxorubicin; Drug Interactions; Drug Synergism; Gene Expression Regulation; Glomerulosclerosis, Focal Segmental; Losartan; Male; Nephrosis, Lipoid; Proteinuria; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Improved renal perfusion prevents disease progression in focal segmental glomerulosclerosis.
Topics: Cilazapril; Dipyridamole; Disease Progression; Glomerulosclerosis, Focal Segmental; Heparin; Humans; Isradipine; Perfusion; Prednisolone; Renal Circulation | 1995 |